SecBot SecBot
SECBOTREPLAY Home › Report › COGT

COGT · Cogent Biosciences presented preclinical data for its novel JAK2 V617F…

Cogent Biosciences, Inc. · PRESS-RELEASE filed Jun 12, 2026 at 08:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 12, 2026 at 08:01 ET

Cogent Biosciences presented preclinical data for its novel JAK2 V617F mutant-selective inhibitor CGT1145 at the EHA Congress, highlighting >100x selectivity over JAK2 WT and JAK1/3 isoforms. The program remains on track for an IND submission in 2026. The data is early-stage and does not involve financial results or regulatory decisions, limiting near-term stock impact.

  • CGT1145 is a potent, selective inhibitor of JAK2 V617F with >100x selectivity over JAK2 WT and JAK1/3 isoforms
  • Preclinical data presented at the 2026 EHA Congress in Stockholm
  • IND submission planned for 2026
  • JAK2 V617F is the most prevalent mutation in BCR-ABL-negative MPNs, occurring in ~95% of polycythemia vera patients and ~50% of primary myelofibrosis / essential thrombocythemia patients

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access